

****Updated January 2017****

MarketVIEW: Japanese encephalitis vaccines (CAT: VAMV011)

Product Name	:	MarketVIEW: Japanese encephalitis vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf) + 1 forecast models (.xls)
Therapeutic Area	:	Endemic/travel vaccines
Publication date	:	January 2017
Catalogue No	:	VAMV011

Background

Japanese Encephalitis (JE) is an enzootic mosquito-borne viral disease where humans are incidental “dead end” hosts. JE currently affects countries of SE Asia and Western Pacific where around 3 billion people are considered at risk. The disease mainly affects children (< 15yrs) in poor rural areas where it can result in 25% mortality (est 10,000 deaths/yr) or residual neuropsychiatric sequelae (30% of cases). There are no specific treatments for JE.

Vaccines for JE have been available for decades and used in large scale routine immunization programs in South Korea, China and Japan. Older mouse brain derived vaccines are gradually being replaced by live-attenuated (**SA 14-14-2, CIBP**) and new vero cell derived inactivated vaccines from both local and Western manufacturers. Countries currently not operating JE vaccination programs are predicted to do so in the next 5 years so increasing demand.

This **MarketVIEW** product is comprised of a comprehensive MS Excel-based model + Summary executive presentation which forecast the potential commercial value of Japanese Encephalitis vaccine(s) across endemic¹ and travel markets² to 2030. The model(s) contain value (\$ m) and volume (mio doses) predictions for endemic countries in all age segments, including catch-up (public sector) down to vaccine type. An up to date review of disease background and epidemiology is included with a review of the competitive environment and forecast GAVI introduction to 2020 and beyond.

¹ China, India, Bangladesh, Indonesia, Viet Nam, Japan, Thailand, Philippines, Pakistan, South Korea, Cambodia, Sri Lanka, Nepal, North Korea, Myanmar, Laos, Malaysia, Timor Leste, Papua New Guinea, and Bhutan; not all the population is at risk in some countries (e.g. India)

² Australia, Canada, Europe and the US. WTO European data covers Finland, France, Germany, Italy, Norway, Spain, Sweden, and the UK

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Japanese Encephalitis epidemiology/vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of travel and endemic vaccines has also been utilised. *****See Bibliography for exact sources.**

PRODUCT CONTENTS:

Updated January 2017 (CAT No: VAMV011)

****This product is composed of a model (.xls)³ and summary presentation (.pdf)

Contents – summary presentation

- Contents
- Authors note
- Executive summary
- Contents
- Author's note
- Executive Summary
- Commercial model: key outputs
- JE vaccines: global endemic value by country to 2030 (\$m)
- JE vaccines: global endemic value by vaccine to 2030 (\$m)
- JE vaccines: global endemic value by age group to 2030 (\$m)
- JE vaccines: global endemic volume by country to 2030 (doses)
- JE vaccines: global endemic volume by age to 2030 (doses)
- JE vaccines: global travel value by origin country to 2030 (\$m)
- JE vaccines: global travel value by vaccine to 2030 (\$m)
- Commercial model assumptions
- Major model inputs (endemic)
- Major model inputs (endemic): country variables
- Major model inputs (endemic): vaccines used
- Major model inputs (travel) (3 slides)
- Major model inputs (military)
- Disease background
- The virus
- Geographic range
- Transmission: overview
- Transmission: enzootic cycle
- Transmission: vector density in Asia
- Clinical features of JE infection
- Clinical features: comparative burden of mosquito borne disease
- JE: treatment and prevention
- JE: epidemiology
- Epidemiology: WHO reported cases
- Epidemiology: risk
- JE: Burden/DALYS

³ Model contents are available on request

Continued.....

Vaccines currently used
Licensed JEV vaccines: brief overview
Chengdu CDIPB: SA14-14-2
Valneva: IXIARO/JESPECT
IXIARO: expected sales revenues by market, 2016
IXIARO: historical sales, 2010-2016
IXIARO: travel market business outlook (2 slides)
IXIARO: revenue forecast to 2026 (\$m)
Sanofi Pasteur: IMOJEV
Other JE vaccines
Competitive landscape
JEBIK V: sales 2012-2016 (f)
Kaketsuken: Encevac – suspension
Competitive landscape: WHO prequalification
JE vaccines: country immunization schedules
Country immunization schedules (cont..)
GAVI funding
GAVI introduction to 2020 and beyond
JE vaccine: pricing (endemic)
Pricing (travel/military)
Pricing: comparative analysis
About **VacZine Analytics**
Disclaimer
Back page

62 slides available in .pdf form

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT [BOTH DELIVERABLES] - **USD \$9,995.00/ £8,915.00** (Region license)*
- PRESENTATION ONLY - **USD \$6,995/ £5,735** (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

#Indicative – exchange made on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. World Tourism Organisation (WTO). Available at: <http://www.e-unwto.org>. Accessed November 2016
2. Duffy MR et al. A survey of US travelers to Asia to assess compliance with recommendations for the use of Japanese encephalitis vaccine. *J Travel Med.* 2013 May-Jun;20(3):165-70.
3. Valneva. Company Presentation. October 2016. Available at: <http://www.valneva.com/en/investors-media/presentations>. Accessed: October 2016
4. Valneva Announces \$42 Million IXIARO Supply Contract with US Government. Available at: http://www.valneva.com/download.php?dir=News_2016&file=2016_03_16_Valneva_US_Military_PR_EN.pdf. Accessed: November 2016
5. Valneva. Company Presentation. March 2014. Available at: <http://www.valneva.com/en/investors-media/presentations>. Accessed: December 2016
6. Report on the growing US military presence in the Asia-Pacific region. Available at: http://www.chinadaily.com.cn/opinion/2016-11/25/content_27481119.htm. Accessed: December 2016
7. Campbell GL, et al. Estimated global incidence of Japanese encephalitis: a systematic review. *Bulletin of the World Health Organization* 2011;89:766-774E. Available at: <http://www.who.int/bulletin/volumes/89/10/10-085233/en/>. Retrieved: October 2016
8. US Centers For Disease Control and Prevention (CDC). Geographic distribution of Japanese encephalitis. Available at: <http://www.cdc.gov/japaneseencephalitis/maps/index.html>. Accessed October 2016
9. WHO. Japanese encephalitis. Fact sheet No 386. December 2015. Retrieved from <http://www.who.int/mediacentre/factsheets/fs386/en/>. Accessed: October 2016
10. US Centers For Disease Control and Prevention. Morbidity and Mortality Weekly Report. Japanese Encephalitis Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). March 12, 2010 / 59(RR01);1-27. Available at: <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5901a1.htm>. Accessed: October 2016.
11. Miller RH et al. Ecological niche modelling to estimate the distribution of Japanese encephalitis virus in Asia. *PLoS Negl Trop Dis.* 2012;6(6):e1678
12. Kakoti G et al. Clinical profile and outcome of Japanese encephalitis in children admitted with acute encephalitis syndrome. *Biomed Res Int.* 2013;2013:152656.
13. WHO. 10 facts on malaria. November 2015 Available at: <http://www.who.int/features/factfiles/malaria/en/>. Accessed October 2016.
14. CDC. Dengue epidemiology. Available at: <http://www.cdc.gov/dengue/epidemiology/>. Accessed October 2016.
15. WHO. Zika situation report. Zika And Potential Complications. 12 February 2016. Available at <http://www.who.int/emergencies/zika-virus/situation-report/en/>. Accessed October 2016.
16. WHO. Yellow fever. *May 2016* Available at: <http://www.who.int/mediacentre/factsheets/fs100/en/> Accessed October 2016.
17. Chikungunya Virus. US Centers For Disease Control and Prevention (CDC). Geographic Distribution. Available at: <http://www.cdc.gov/chikungunya/geo/index.html>. Accessed October 2016.
18. Wang L. et al. Deaths associated with Japanese encephalitis, China, 2005-2010. *Clin Infect Dis.* 2013 Mar;56(5):752.
19. WHO. Global Health Observatory data repository. Japanese encephalitis - number of reported cases. Available at: <http://apps.who.int/gho/data/view.main>. Accessed: October 2016
20. Sunwoo JS et al. Reemergence of Japanese Encephalitis in South Korea, 2010-2015. *Emerg Infect Dis.* 2016 Oct;22(10):1841-3.
21. Gurav YK et al. A large outbreak of Japanese encephalitis predominantly among adults in northern region of West Bengal, India. *J Med Virol.* 2016 Nov;88(11):2004-11.
22. Li X et al. The Spatio-temporal Distribution of Japanese Encephalitis Cases in Different Age Groups in Mainland China, 2004 - 2014. *PLoS Negl Trop Dis.* 2016 Apr 6;10(4):e0004611
23. Hills SL, et al. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. *Am J Trop Med Hyg* 2010; 82:930-936.
24. Ratnam I et al. Low risk of Japanese encephalitis in short-term Australian travelers to Asia. *J Travel Med.* 2013 May-Jun;20(3):206-8.
25. Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. *MMWR Morb Mortal Wkly Rep.* 2013 Nov 15;62(45):898-900.
26. PATH. SA14-14-2 Japanese encephalitis vaccine. Available at: <https://www.path.org/publications/files/SA14142-fact-sheet-1013.pdf>. Accessed October 2016.
27. WHO. Recommendations for routine immunization, September 2016. Available at: http://www.who.int/immunization/policy/immunization_tables/en/. Accessed: October 2016
28. Biological E launches Japanese encephalitis vaccine. Available at: <http://www.businessstoday.in/sectors/pharma/japanese-encephalitis-vaccine-jeev-biological-e/story/188074.html>. Accessed: November 2016.
29. Valneva. Company Presentations (FY 2014 results; Q3 2015 analyst presentation). Available at: <http://www.valneva.com/en/investors-media/presentations>. Accessed: October 2016

30. Chokephaibulkit K et al. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children. *Vaccine*. 2016 Sep 26. pii: S0264-410X(16)30831-3.
31. Sanofi Pasteur proves the excellence of Vero cell culture-derived Japanese encephalitis vaccine Imojev through global and domestic clinical trials . Available at: [http://www.sanofipasteur.com/en/Documents/PDF/PR-locaux/Press%20Releas%20Sanofi%20Pasteur%20holds%20Imojev%20press%20conference for%20SP%20web.pdf/](http://www.sanofipasteur.com/en/Documents/PDF/PR-locaux/Press%20Releas%20Sanofi%20Pasteur%20holds%20Imojev%20press%20conference%20for%20SP%20web.pdf/) Accessed: October 2016
32. Bharat Biotech launches JENVAC™ - a Novel fully Indigenous Inactivated Japanese Encephalitis vaccine. Oct 04, 2013. Available at: <http://www.bharatbiotech.com/media/press-release/?pryear=2013>. Accessed: November 2016
33. India launches vaccine to prevent Japanese encephalitis. October 4, 2013. Available at: <http://www.thehindu.com/news/national/india-launches-vaccine-to-prevent-japanese-encephalitis/article5201813.ece>. Accessed: October 2016
34. India launches first indigenous vaccine for Japanese encephalitis. Available at: <http://www.livemint.com/Industry/NVvjUE8DUW3pphiHFmIA2H/India-launches-first-indigenous-vaccine-for-Japanese-encepha.html>. Accessed: November 2016
35. Inclusion of a Japanese Encephalitis Vaccine in the Korean NIP. Available at: <http://www.kaketsuken.or.jp/en/press-release/55.html>. Accessed: October 2016
36. WHO PQ vaccines. Available at: https://extranet.who.int/gavi/PQ_Web/. Accessed October 2016.
37. UNICEF. Japanese encephalitis vaccines supply market update - July 2015. Available at: http://www.unicef.org/supply/index_82707.html. Accessed: October 2016
38. Detailed Import Data of products under HS Code 30022017. Available at: <https://www.zauba.com/import-/hs-code-30022017/p-5-hs-code.html>. Accessed: November 2016
39. Japanese encephalitis: China denies India's request for additional doses of vaccine. By Jayalakshmi K March 9, 2015 04:17 GMT. Available at: <http://www.ibtimes.co.uk/japanese-encephalitis-china-denies-indias-request-additional-doses-vaccine-1491038>. Accessed: November 2016
40. Vashishtha VM et al Vaccination Policy for Japanese Encephalitis in India: Tread with Caution! *Indian Pediatr*. 2015 Oct;52(10):837-9.
41. Press Information Bureau Government of India Ministry of Health and Family. December 2015. Welfare. Available at: <http://pib.nic.in/newsite/PrintRelease.aspx?relid=133853>. Accessed October 2016
42. Guidelines for Applications for Japanese Encephalitis vaccines under GAVI's New and underused Vaccines Support (NVS) in 2016 Document dated: October 2015
43. UNICEF. Vaccine Price Data. Available at: http://www.unicef.org/supply/index_57476.html. Accessed: October 2016
44. Yin Z et al. An economic evaluation of the use of Japanese encephalitis vaccine in the expanded program of immunization of Guizhou province, China. *Vaccine*. 2012 Aug 10;30(37):5569-77.
45. Thai Travel Clinic, Hospital for Tropical Diseases. Available at: <http://www.thaitravelclinic.com/cost.html>. Accessed: October 2016
46. Mitsubishi Tanabe Pharma Corporate Report 2016. Available at: www.mt-pharma.co.jp/shared/show.php?url=../e/ir/annual/index.html. Accessed: October 2016
47. BNF. IXIARO. Available at: <https://www.evidence.nhs.uk/formulary/bnf/current/14-immunological-products-and-vaccines/144-vaccines-and-antisera/japanese-encephalitis-vaccine/japanese-encephalitis-vaccine/ixiaro>. Accessed: November 2016
48. Travel Clinic Prices - - CityDoc. Available at: <https://www.citydoc.org.uk/travel-clinic-fees/>. Accessed November 2016
49. New Japanese encephalitis vax launched. Available at: <http://www.australiandoctor.com.au/news/latest-news/new-japanese-encephalitis-vax-launched>. Accessed November 2016
50. Victoria Travel Clinic. Vaccination Price List. Available at: <http://www.victoriatravelclinic.com/travel-vaccinations/>. Accessed November 2016
51. CDC Vaccine Price List. Available at: <http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/>. Accessed November 2016
52. Prescription Pricelist - Priceline Pharmacy. Available at: https://www.priceline.com.au/media/wysiwyg/PDF/Prescription_Price.pdf. Accessed November 2016

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009